Anti-PDCD1/PD-1 therapeutic antibody (Pre-made Zimbirelimab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pre-made Zimbirelimab benchmark antibody (Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-1058
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Products Name (INN Index) | Pre-Made Zimbirelimab Biosimilar, Whole Mab, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody |
---|---|
INN Name | zimbirelimab |
Target | PDCD1 |
Format | Whole mAb |
Derivation | Human |
Species Reactivity | Human |
CH1 Isotype | IgG4 – lambda |
VD LC | IgG4 – lambda |
Highest_Clin_Trial (Jan '20) | NA |
Est. Status | NA |
100% SI Structure | NA |
99% SI Structure | NA |
95-98% SI Structure | NA |
Year Proposed | NA |
Year Recommended | NA |
Companies | Arcus?Biosciences, Inc. (Hayward CA USA) |
Conditions Approved | NA |
Conditions Active | NA |
Conditions Discontinued | NA |
Development Tech | OmniRat (Open Monoclonal Technology Inc (OMT)) |
Previous Name | NA |
Gm Offical Target Name | PDCD1 |
Package |
Genemeidi Omicron Variant Products
test
Previous slide
Next slide